Qiagen N.V. stock (NL0012169213): Q1 earnings meet EPS but miss revenue

Qiagen N.V. reported Q1 2026 earnings on May 6 with EPS of $0.54 matching estimates, but revenue of $492.32 million fell short of $496.15 million expected. The company issued full-year guidance below consensus.

Qiagen N.V. released its first-quarter 2026 earnings on May 6, 2026, posting earnings per share (EPS) of $0.54, which aligned with analyst consensus estimates of $0.54, MarketBeat as of May 2026. Quarterly revenue came in at $492.32 million, missing the forecasted $496.15 million. For the full year, Qiagen guided EPS to $2.43 and revenue to $2.1 billion, both below consensus expectations of $2.51 EPS and $2.2 billion in sales.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Qiagen N.V.
• Sector/industry: Life Sciences / Diagnostics
• Headquarters/country: Netherlands
• Core markets: US, Europe, Asia
• Key revenue drivers: Sample technologies, assays, bioinformatics
• Home exchange/listing venue: NYSE (QGEN)
• Trading currency: USD

Qiagen N.V.: core business model

Qiagen N.V. develops and markets sample collection, purification, and analysis technologies for molecular diagnostics, academic research, and applied testing markets worldwide. The company operates through three main segments: Genomics, Nova Century, and PCR Consumables, providing instruments, consumables, and related services. Its platforms enable the processing of DNA, RNA, and proteins from various samples, serving customers in healthcare, forensics, and food safety.

Listed on the NYSE under ticker QGEN, Qiagen N.V. generates significant revenue from the US market, making it relevant for American investors tracking biotech and diagnostics firms. Trailing twelve-month EPS stood at $1.91 as of the Q1 report publication, with a P/E ratio of 17.26, MarketBeat as of May 2026.

Main revenue and product drivers for Qiagen N.V.

Qiagen N.V.’s primary revenue streams come from consumables and instruments in sample technologies (over 50% of sales), followed by assays and bioinformatics software. Key products include the QIAcube Connect for automated nucleic acid purification and the QuantiFERON test for TB detection. The company reported Q1 2026 revenue of $492.32 million, reflecting steady demand in genomics and precision medicine.

Full-year 2025 financials, published earlier, showed growth in these areas, though specific figures for prior periods are noted with their reporting dates. US sales represent a core driver, bolstered by partnerships with pharma and clinical labs amid rising demand for next-generation sequencing.

Industry trends and competitive position

The global molecular diagnostics market is expanding due to advances in personalized medicine and infectious disease testing, with Qiagen N.V. holding a strong position through its end-to-end workflow solutions. Competitors include Thermo Fisher and Roche, but Qiagen differentiates via specialized sample prep kits. Sector growth supports US investor interest, as the firm derives substantial exposure from American healthcare spending.

Why Qiagen N.V. matters for US investors

Qiagen N.V.’s NYSE listing and heavy US revenue footprint tie its performance to American biotech trends, including gene therapy and companion diagnostics. With products integrated into US clinical trials and labs, the stock offers exposure to healthcare innovation without pure domestic operations risks.

Conclusion

Qiagen N.V.’s Q1 2026 results showed EPS in line with expectations but revenue slightly below, alongside conservative full-year guidance. The company maintains a solid position in molecular diagnostics, with ongoing demand in key markets. Investors monitor upcoming quarters for execution on growth initiatives amid sector tailwinds.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.